Last reviewed · How we verify
Tirotrisin (TYROTHRICIN)
Tirotrisin (generic name: TYROTHRICIN) is a tyrothricin drug. It is currently in Phase 2 development.
Tirotrisin works by binding to the bacterial ribosome and inhibiting protein synthesis.
Tirotrisin is a protein modality. It is also known by several synonyms, including BACTRATYCIN, COLTIROT, DERMOTRICINE, HYDROTRICINE, MARTRICIN, and NSC-757363.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TYROTHRICIN |
|---|---|
| Drug class | tyrothricin |
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Tirotrisin is a special molecule that blocks the bacterial factories from making proteins, effectively stopping the infection.
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers (PHASE1)
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers (PHASE1)
- Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis (PHASE4)
- Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (NA)
- Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage (PHASE3)
- Tyrosur® Gel-Investigation on Wound Healing Efficacy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tirotrisin CI brief — competitive landscape report
- Tirotrisin updates RSS · CI watch RSS
Frequently asked questions about Tirotrisin
What is Tirotrisin?
How does Tirotrisin work?
What is the generic name of Tirotrisin?
What drug class is Tirotrisin in?
What development phase is Tirotrisin in?
Related
- Drug class: All tyrothricin drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing